Rivastigmine Tartrate

ACCESS ALL DATA, CHEMISTRY

ACTIVE PHARMA INGREDIENTS

38 API Suppliers, 18 USDMF, 12 CEP/COS, 15 EU WC, 19 KDMF, 6 NDC API, 24 Listed Suppliers, $ API Reference Price

DEVELOPMENTS

5 Drugs in Development

5 Drugs in Development

INTERMEDIATES

9 Intermediates Suppliers

9 Intermediates Suppliers

FINISHED DOSAGE FORMULATIONS

120 FDF Dossiers, 46 FDA Orange Book, 40 Europe, 29 Canada, 5 Listed Dossiers

DRUG PRODUCT COMPOSITIONS

CAPSULE;ORAL - EQ 1.5MG BASE **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**, CAPSULE;ORAL - EQ 3MG BASE **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**, CAPSULE;ORAL - EQ 4.5MG BASE **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**, CAPSULE;ORAL - EQ 6MG BASE **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**

RELATED EXCIPIENT COMPANIES

4 SPI Pharma, 8 DKSH, 3 Faran Shimi Pharmaceutical, 9 Gangwal Healthcare, 1 Nanjing Well Pharmaceutical, 4 ACG Worldwide, 5 Anhui Sunhere Pharmaceutical Excipients Co.,Ltd, 8 BASF, 10 Corel Pharma Chem, 2 DFE Pharma, 1 Finar, 6 Gangwal Chemicals, 5 Ideal Cures Pvt Ltd, 2 Ingredion Pharma Solutions, 15 Kerry, 3 Kima Chemical, 6 Lonza Capsugel, 10 Microlex e.U, 1 Novo Excipients, 1 Pharmatrans-Sanaq, 3 Pluviaendo, 2 Prachin Chemical, 1 Qianhao Chemical (Hebei) Co., Ltd, 2 Qualicaps, 17 Roquette, 8 Seppic, 4 Shanghai Shenmei Pharmaceutical Technology Co., Ltd, 8 Sigachi Industries, 2 The Dow Chemical Company, 1 Valens Pharmachem, 2 Vasa Pharmachem

EXCIPIENTS BY APPLICATIONS

48 Coating Systems & Additives, 42 Fillers, Diluents & Binders, 22 Direct Compression, 21 Controlled & Modified Release, 19 Thickeners and Stabilizers, 16 Lubricants & Glidants, 12 Granulation, 11 Film Formers & Plasticizers, 11 Co-Processed Excipients, 10 Disintegrants & Superdisintegrants, 9 Empty Capsules, 9 Taste Masking, 6 Chewable & Orodispersible Aids, 5 Coloring Agents, 5 Emulsifying Agents, 5 Topical, 4 Vegetarian Capsules, 4 API Stability Enhancers, 3 Solubilizers, 2 Rheology Modifiers, 1 Parenteral, 1 Surfactant & Foaming Agents

DIGITAL CONTENT

7 NEWS #PharmaBuzz

7 NEWS #PharmaBuzz

GLOBAL SALES INFORMATION

12 Finished Drug Prices

12 Finished Drug Prices

MARKET PLACE

3 APIs

3 APIs

PATENTS & EXCLUSIVITIES

11 Health Canada Patents

11 Health Canada Patents

REF. STANDARDS & IMPURITIES

3 EDQM, 2 USP, 2 Others

$ Xls

Filters

Xls

USFDA APPLICATION NUMBER - 20823 / DOSAGE - CAPSULE;ORAL - EQ 4.5MG BASE **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**

Ingredient Name	Basis of Strength	Strength
Active Ingredient/Active Moiety
RIVASTIGMINE TARTRATE(UNII: 9IY2357JPE) (RIVASTIGMINE - UNII:PKI06M3IW0)	RIVASTIGMINE	6mg \| 4.5mg \| 3mg \| 1.5mg

Inactive Ingredients

Ingredient Name	Avera McKennan Hospital	Novartis Pharmaceuticals Corporation	Sandoz Inc
CELLULOSE, MICROCRYSTALLINE(OP1R32D61U)
FERRIC OXIDE RED(1K09F3G675)
FERRIC OXIDE YELLOW(EX438O2MRT)
GELATIN(2G86QN327L)
HYPROMELLOSES(3NXW29V3WO)
MAGNESIUM STEARATE(70097M6I30)
SILICON DIOXIDE(ETJ7Z6XBU4)
TITANIUM DIOXIDE(15FIX9V2JP)

Drug Product Composition: Rivastigmine Tartrate